临床试验进展 - XPro在阿尔茨海默病的II期临床试验已完全入组，预计2025年6月公布顶线认知结果[5] - CORDStrom在隐性营养性表皮松解症（RDEB）完成了盲法随机试验，计划于2026年提交美国生物制品许可申请（BLA）[5] - INKmune在转移性去势抵抗性前列腺癌的I期剂量递增队列已完成，2025年将进行开放标签的II期试验[5] 市场机会与用户数据 - CORDStrom的市场机会预计超过10亿美元，针对美国、英国和欧盟的4000多名RDEB患者[50] - CORDStrom计划于2025年底提交BLA申请，预计在2026年获得美国、英国和欧盟的批准[53] 试验结果与疗效 - XPro在I期试验中显示出对神经炎症的剂量依赖性减少，CSF生物标志物显著降低[16] - XPro在I期试验中，1mg/kg剂量每周皮下注射12周后，pTau217生物标志物显著降低，p<0.0001[19] - CORDStrom在30名儿童患者的试验中，未报告任何与CORDStrom相关的严重不良事件[52] - CORDStrom的顶线结果显示在瘙痒评估、临床评分和生活质量方面有显著改善[52] - CORDStrom治疗在所有患者组中均显示出瘙痒改善，且10名中有13名受访者确认其在瘙痒、伤口护理和生活质量方面的临床益处[64] - CORDStrom的主要终点为瘙痒，次要终点包括疼痛、EBDASI、iscorEB、生活质量和伤口愈合[67] - 在6个月的iscorEB结果中，CORDStrom治疗组的评分相较于基线有显著改善[69] - CORDStrom治疗的耐受性良好，使得治疗过程更加顺利[64] - CORDStrom的疗效在中重度RDEB患者中经过3个周期的治疗（每周期2剂）进行评估[67] - CORDStrom治疗显示出对RDEB的系统性益处，改善了与疾病相关的额外皮肤外表现[68] 未来展望 - CORDStrom的BLA提交预计在2026年上半年完成[83] - CORDStrom的开放标签试验目标包括将瘙痒的减少与伤口愈合的改善相关联[64]

Analyst’s Disclosure:I/we have a beneficial long position in the shares of INMB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a partic ...

XPro™ Treatment Post-TBI Prevents Short- and Long-Term Alzheimer’s-like Pathology in transgenic mice Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease is collaborating with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia on the interaction of TBI and AD. ...

INmune Bio, Inc. (NASDAQ: INMB ) announced Q1 2025 business and financial results on May 8th, 2025, beating the analyst’s estimates. More importantly, the company claims to be on track for sharing results of theOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to assess the potential of novel tre ...

INmune Bio (INMB) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants David Moss - Chief Financial OfficerRaymond Tesi - CEO & ChairmanMark Lowdell - Chief Scientific Officer & Chief Manufacturing OfficerDenis Reznik - Senior Equity Research AssociateChristopher Barnum - VP - NeuroscienceGeorge Farmer - Managing DirectorLaura Suriel - Equity Research Associate Conference Call Participants Thomas Shrader - MD & Healthcare Analyst Operator Greetings, and welcome to the Immune Bio First Quarter ...

INmune Bio (INMB) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants David Moss - Chief Financial OfficerRaymond Tesi - CEO & ChairmanMark Lowdell - Chief Scientific Officer & Chief Manufacturing OfficerDenis Reznik - Senior Equity Research AssociateChristopher Barnum - VP - NeuroscienceGeorge Farmer - Managing DirectorLaura Suriel - Equity Research Associate Conference Call Participants Thomas Shrader - MD & Healthcare Analyst Operator Greetings, and welcome to the Immune Bio First Quarter ...

INmune Bio (INMB) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the Immune Bio First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. As a reminder, this conference is being recorded. A transcript will follow within twenty four hours of this conference call. At this time, it is my pleasure to introduce Mr. David Ma, CFO of Immune ...

Exhibit 99.1 INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update Conference Call Today at 4:30pm ET BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical- stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update. Q1 2025 and Recent Corporate Highlights DN-TNF Platform Highligh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Identification No.) 225 NE Mizner Blvd., S ...

Conference Call Today at 4:30pm ETBOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update. Q1 2025 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected in the secon ...